Published in Am J Cardiol on August 15, 2005
Myocardial infarction in major noncardiac surgery: Epidemiology, pathophysiology and prevention. Heart Int (2006) 0.77
Coronary artery disease: to cath or not to cath? When and how best to cath: those are the remaining questions. Am J Cardiovasc Dis (2013) 0.75
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA (2002) 11.06
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation (2002) 4.99
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation (2012) 4.13
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation (2003) 3.38
Contemporary use of embolic protection devices in saphenous vein graft interventions: Insights from the stenting of saphenous vein grafts trial. Catheter Cardiovasc Interv (2010) 3.24
Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J (2010) 3.22
Incidence, retrieval methods, and outcomes of stent loss during percutaneous coronary intervention: a large single-center experience. Catheter Cardiovasc Interv (2005) 3.20
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol (2003) 3.13
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med (2004) 3.07
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05
Body mass index: a risk factor for unstable angina and myocardial infarction in patients with angiographically confirmed coronary artery disease. Circulation (2003) 2.77
Transcatheter aortic valve implantation: assessing the learning curve. JACC Cardiovasc Interv (2011) 2.63
Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Four-year recurrence rate and prognosis of the apical ballooning syndrome. J Am Coll Cardiol (2007) 2.53
Trends in cause of death after percutaneous coronary intervention. Circulation (2014) 2.52
Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J Am Coll Cardiol (2005) 2.51
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. J Am Coll Cardiol (2007) 2.47
Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation (2007) 2.47
Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J (2004) 2.42
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol (2008) 2.38
Outcomes of stent thrombosis and restenosis during extended follow-up of patients treated with bare-metal coronary stents. Circulation (2007) 2.31
Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J (2004) 2.29
A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. J Am Coll Cardiol (2009) 2.29
Intravascular ultrasound-guided treatment for angiographically indeterminate left main coronary artery disease: a long-term follow-up study. J Am Coll Cardiol (2005) 2.21
Treatment of saphenous vein bypass grafts with ultrasound thrombolysis: a randomized study (ATLAS). Circulation (2003) 2.21
Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation (2004) 2.21
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol (2003) 2.17
Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. Mayo Clin Proc (2004) 2.11
Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA (2007) 2.10
Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med (2012) 2.09
The long-term effect of coronary stenting on epicardial and microvascular endothelial function. Circ Cardiovasc Interv (2012) 2.03
The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol (2002) 2.03
Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol (2005) 2.00
Rheolytic thrombectomy with Angiojet in thrombus-containing lesions. Catheter Cardiovasc Interv (2002) 1.98
Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation (2011) 1.94
Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol (2006) 1.90
Effect of long-term hormone replacement therapy on coronary endothelial function in postmenopausal women. Mayo Clin Proc (2004) 1.80
Clinical determinants of radiation dose in percutaneous coronary interventional procedures: influence of patient size, procedure complexity, and performing physician. JACC Cardiovasc Interv (2011) 1.80
Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience. J Am Coll Cardiol (2008) 1.78
Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation (2012) 1.77
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med (2009) 1.76
Long-term outcomes of fractional flow reserve-guided vs. angiography-guided percutaneous coronary intervention in contemporary practice. Eur Heart J (2013) 1.76
Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J (2006) 1.73
Factors associated with 30-day readmission rates after percutaneous coronary intervention. Arch Intern Med (2011) 1.70
Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol (2007) 1.68
Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol (2009) 1.67
Ambulation 1 hour after diagnostic cardiac catheterization: a prospective study of 1009 procedures. Mayo Clin Proc (2006) 1.67
Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol (2004) 1.64
Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina. Eur Heart J (2006) 1.63
Readmission in the 30 days after percutaneous coronary intervention. JACC Cardiovasc Interv (2013) 1.63
Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol (2002) 1.62
Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res (2006) 1.61
Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Am Heart J (2004) 1.60
Coronary endothelial dysfunction in patients with early coronary artery disease is associated with the increase in intravascular lipid core plaque. Eur Heart J (2013) 1.59
Role of circulating osteogenic progenitor cells in calcific aortic stenosis. J Am Coll Cardiol (2012) 1.59
Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. Blood (2002) 1.59
Coronary microcirculatory vasodilator function in relation to risk factors among patients without obstructive coronary disease and low to intermediate Framingham score. Eur Heart J (2009) 1.58
Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv (2011) 1.56
Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions. Circulation (2006) 1.55
Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J (2010) 1.55
Sex differences in atheroma burden and endothelial function in patients with early coronary atherosclerosis. Eur Heart J (2008) 1.53
Remote ischemic preconditioning immediately before percutaneous coronary intervention does not impact myocardial necrosis, inflammatory response, and circulating endothelial progenitor cell counts: a single center randomized sham controlled trial. Catheter Cardiovasc Interv (2012) 1.51
Percutaneous coronary intervention at centers with and without on-site surgery: a meta-analysis. JAMA (2011) 1.51
Treatment of obstructive sleep apnea is associated with decreased cardiac death after percutaneous coronary intervention. J Am Coll Cardiol (2007) 1.49
Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv (2004) 1.48
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J (2011) 1.47
One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. EuroIntervention (2013) 1.47
Immediate ambulation following diagnostic coronary angiography procedures utilizing a vascular closure device (The Closer). J Invasive Cardiol (2002) 1.47
Percutaneous revascularization for stable coronary artery disease temporal trends and impact of drug-eluting stents. JACC Cardiovasc Interv (2010) 1.47
Outcomes of elderly patients with cardiogenic shock treated with early percutaneous revascularization. Am Heart J (2004) 1.47